Arsenal Capital Partners Acquires Endpoint Clinical and Fortrea Patient Access from Fortrea

Arsenal Capital Partners Invests $449M in Certara

December 8, 2022

Biotechnology

Arsenal Capital Partners closed a previously announced $449 million stock purchase in Certara, acquiring shares from funds controlled by EQT Private Equity and becoming a long-term minority investor. As part of the transaction Arsenal appointed Operating Partner David Spaight to Certara's board while Stephen McLean remains a director; Arsenal agreed to a two-year lock-up on the newly purchased shares.

Arsenal Capital Partners Acquires BresMed Health Solutions

February 26, 2020

Healthcare Services

Arsenal Capital Partners acquired BresMed Health Solutions as the first investment to form a new value demonstration platform focused on market access, health economics, outcomes research, patient preference and real-world evidence. BresMed — a global health economics and outcomes research consultancy with more than 150 staff across the U.K., Ireland, the Netherlands, the U.S. and India — will continue to be led by founder Nic Brereton and will join Arsenal’s new platform led operationally by Jon Williams.

Advarra Acquires Forte

September 5, 2019

Software

Advarra, a leading provider of IRB and research compliance services, announced its intent to acquire Forte, a market-leading provider of clinical research technology including the OnCore CTMS. The deal (Forte sold by Primus Capital) expands Advarra's site-centric technology and eClinical capabilities to better serve academic medical centers, cancer centers, and health systems.

ERT Merges with Bioclinica to Create Global Clinical Trial Endpoint Leader

December 10, 2020

Healthcare Services

ERT has merged with Bioclinica to create a global leader in clinical trial endpoint technology, combining Bioclinica's imaging and eClinical capabilities with ERT's expertise in eCOA, cardiac safety, respiratory and wearables. The transaction was completed in 2021 with Cinven (Bioclinica's owner) becoming a significant minority shareholder in ERT alongside Nordic Capital, Astorg and Novo Holdings A/S.

Arsenal Capital Partners Acquires Caprion Biosciences from GHO Capital

July 31, 2019

Healthcare Services

Arsenal Capital Partners has acquired Caprion Biosciences from GHO Capital Partners LLP. Caprion is a specialist laboratory services provider focused on immune monitoring (flow cytometry) and quantitative proteomics for pharmaceutical and biotech R&D, with facilities across North America, Europe and Australia.

Financial Times Acquires Controlling Stake in Endpoints News

April 3, 2023

Media & Entertainment

The Financial Times has acquired a majority stake in Endpoints News, a US-based biopharma news publisher, to expand its footprint in the United States and deepen its coverage of the biopharmaceutical sector. Endpoints, founded and headquartered in Lawrence, Kansas, publishes daily newsletters, operates a website and hosts industry events with a large subscriber base.